54,297 Omeros Corporation $OMER Shares Purchased by Profund Advisors LLC

Profund Advisors LLC raised its position in Omeros Corporation (NASDAQ:OMER) by 206.3% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 80,616 shares of the biopharmaceutical company’s stock after purchasing an additional 54,297 shares during the period. Profund Advisors LLC owned about 0.11% of Omeros worth $1,535,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of OMER. VIRGINIA RETIREMENT SYSTEMS ET Al lifted its stake in shares of Omeros by 13.6% during the third quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 17,500 shares of the biopharmaceutical company’s stock valued at $333,000 after buying an additional 2,100 shares during the period. China Universal Asset Management Co. Ltd. boosted its position in Omeros by 3.9% during the third quarter. China Universal Asset Management Co. Ltd. now owns 15,708 shares of the biopharmaceutical company’s stock worth $302,000 after acquiring an additional 589 shares during the last quarter. Sterling Capital Management LLC grew its stake in Omeros by 75.3% in the 3rd quarter. Sterling Capital Management LLC now owns 1,764 shares of the biopharmaceutical company’s stock worth $34,000 after acquiring an additional 758 shares during the period. GK Wealth Management LLC acquired a new position in Omeros in the 3rd quarter valued at $65,000. Finally, State Street Corp raised its holdings in Omeros by 20.9% in the 2nd quarter. State Street Corp now owns 2,319,906 shares of the biopharmaceutical company’s stock valued at $22,062,000 after acquiring an additional 400,331 shares during the last quarter. 48.79% of the stock is owned by institutional investors and hedge funds.

Omeros Stock Performance

Omeros stock opened at $17.83 on Tuesday. Omeros Corporation has a 1 year low of $6.24 and a 1 year high of $21.24. The firm has a 50 day moving average price of $18.49 and a 200 day moving average price of $13.49. The company has a market cap of $1.29 billion, a price-to-earnings ratio of 13.93 and a beta of 2.57.

Omeros (NASDAQ:OMER) last posted its quarterly earnings results on Wednesday, August 12th. The biopharmaceutical company reported $0.02 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.29. The company had revenue of $28.53 million for the quarter, compared to analysts’ expectations of $12.69 million. Sell-side analysts predict that Omeros Corporation will post -0.37 EPS for the current year.

Analyst Ratings Changes

A number of brokerages have weighed in on OMER. HC Wainwright reissued a “buy” rating on shares of Omeros in a research note on Monday, July 27th. Zacks Research downgraded Omeros from a “strong-buy” rating to a “hold” rating in a research report on Monday, July 13th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $22.00 price objective on shares of Omeros in a research report on Wednesday, October 14th. Wall Street Zen upgraded Omeros from a “hold” rating to a “buy” rating in a research note on Saturday, August 15th. Finally, Weiss Ratings upgraded Omeros from a “hold (c-)” rating to a “hold (c)” rating in a research report on Thursday, October 8th. Three investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat, Omeros presently has a consensus rating of “Moderate Buy” and a consensus target price of $30.33.

Insider Transactions at Omeros

In related news, Director Arnold C. Hanish sold 10,000 shares of the company’s stock in a transaction on Thursday, August 27th. The shares were sold at an average price of $18.95, for a total transaction of $189,500.00. Following the completion of the sale, the director directly owned 5,000 shares of the company’s stock, valued at approximately $94,750. This represents a 66.67% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Peter B. Cancelmo sold 25,000 shares of the stock in a transaction that occurred on Monday, August 31st. The shares were sold at an average price of $18.54, for a total transaction of $463,500.00. Following the completion of the sale, the vice president directly owned 200 shares of the company’s stock, valued at $3,708. This trade represents a 99.21% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 105,906 shares of company stock valued at $1,989,705. Corporate insiders own 10.50% of the company’s stock.

Omeros Profile

Omeros Corporation (NASDAQ: OMER) is a biopharmaceutical company focused on discovering, developing and commercializing therapies for disorders involving the complement, immune and coagulation systems. The company has also developed a pipeline of investigational therapies aimed at treating serious diseases involving complement activation and immune-system dysfunction. The company is headquartered in Seattle, Washington, and was founded in 1994.

Its leading investigational programs have included narsoplimab, which targets the lectin pathway of the complement system, and OMS906, an antibody designed to inhibit MASP-3 and regulate the alternative pathway.